Skip to main content

Table 3 List of clinical trials included for PFS analysis

From: Agnostic evaluation of ipilimumab and nivolumab association: a metanalysis

Study

No. patients

Median PFS (months)

HR

CA209-067

n + i = 314

n = 316

n + i = 11.5

n = 6.93

HR 0.79

CA209-227 (PFS TMB High)

n + i = 101

n = 102

1 yr

n + i = 42%

n = 29%

HR 0.75

CA209-227 (PFS PD-L1 > 1%)

n + i = 396

n = 396

n + i = 5.1

n = 4.2

HR 0.83